Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity of CAR T cells in cancer therapy.

Nature reviews. Clinical oncology - 1 Jun 2021

Wagner Dimitrios L, Fritsche Enrico, Pulsipher Michael A, Ahmed Nabil, Hamieh Mohamad, Hegde Meenakshi, Ruella Marco, Savoldo Barbara, Shah Nirali N, Turtle Cameron J, Wayne Alan S, Abou-El-Enein Mohamed

Abstract excerpt

Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen receptors (CARs) have shown remarkable clinical responses and are commercially available for the treatment of patients with certain advanced-stage B cell malignancies. Nonetheless, several trials have revealed pre-existing and/or treatment-induced immune responses to the mouse-derived single-chain variable fragments...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Editing

Share to Immunity, Cellular

Share to Immunotherapy, Adoptive

Share to Neoplasms

Share to Receptors, Chimeric Antigen

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 33633361
DOI: 10.1038/s41571-021-00476-2
PMCID: PMC8923136

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of CAR T cells in cancer therapy.PMID 33633361Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cellsSemantic proximity Read ↗

CAR‐T‐cell products in solid tumors: Progress, challenges, and strategiesSemantic proximity Read ↗

Chimeric antigen receptor transduced T cells: Tuning up for the next generationSemantic proximity Read ↗

Chimeric Antigen Receptors: A Paradigm Shift in ImmunotherapySemantic proximity Read ↗

Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T CellsSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

Chimeric Antigen Receptors Modified T-Cells for Cancer TherapySemantic proximity Read ↗

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read ↗

Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.